Clark Estates’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Clark Estates's REGN Position: Q1 2023 in Review
Clark Estates sold out of Regeneron Pharmaceuticals (REGN) in Q1 2023, closing a stake of 6,400 shares — an estimated $4.62M sold.
Clark Estates first reported a position in REGN in Q1 2022 and held it in 4 quarters. The position peaked at $4.62M in Q4 2022. 1,191 funds tracked by Wall St. Rank hold REGN as of Q1 2023.
- Clark Estates reported no remaining Regeneron Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
- Clark Estates sold 6,400 Regeneron Pharmaceuticals shares in Q1 2023, an estimated $4.62M.
- Clark Estates first reported a position in Regeneron Pharmaceuticals in Q1 2022 and held it in 4 quarters.
- Clark Estates's Regeneron Pharmaceuticals position peaked at $4.62M in Q4 2022.
- 1,191 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.
Based on Clark Estates's 13F filing for Q1 2023, filed 12 May 2023.